In ophthalmology, Regeneron's development of Eylea® (aflibercept) has been transformative. Approved by the U.S. Food and Drug Administration (FDA) in 2011, Eylea is used to treat various retinal diseases, including age-related macular degeneration and diabetic retinopathy. The drug has become a cornerstone in retinal therapy, with U.S. sales reaching $1.53 billion in a recent quarter, reflecting its critical role in preserving vision for millions of patients.

In the realm of immunology, Regeneron, in collaboration with Sanofi, developed Dupixent® (dupilumab), an anti-inflammatory medication approved for conditions such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis. Dupixent has significantly improved disease management and patient quality of life, with quarterly sales reaching $3.56 billion, underscoring its widespread adoption and effectiveness.

During the COVID-19 pandemic, Regeneron applied its expertise in infectious diseases to develop REGEN-COV® (casirivimab and imdevimab), a monoclonal antibody cocktail designed to prevent and treat COVID-19. The therapy received Emergency Use Authorization from the FDA in November 2020 and was utilized to reduce viral load and improve clinical outcomes in patients. However, due to the emergence of variants less susceptible to this treatment, the FDA revoked its authorization in December 2024.

Regeneron's commitment to scientific excellence is further exemplified by its proprietary VelociSuite® technologies, which have accelerated the discovery and development of fully human antibodies, contributing to a robust pipeline of therapeutics across various disease areas.

With a focus on addressing unmet medical needs through innovative biotechnological approaches, Regeneron continues to make significant contributions to global health, solidifying its position as a Med Honors Top Pharmaceutical Innovator.